Anda di halaman 1dari 16

CONTACT INFO PUBLIC LISTINGS

76 Stafford Street, Suite 302 TSX Venture


Toronto, Ontario M6J 2S1 Ticker: MJN
Office: (416) 504-0004
georgia@thecronosgroup.com OTC Markets
Ticker: PRMCF

Cronos Group, is a geographically diversified and vertically integrated cannabis company that operates two wholly-owned Licensed Producers ("LPs") regulated within Health
Canada's Access to Cannabis for Medical Purposes Regulations (the "ACMPR") and holds a portfolio of minority investments in other Licensed Producers and ACMPR applicants.
DISCLAIMERS AND CAUTIONARY STATEMENTS
The information found herein, and any other materials provided by Cronos Group (the Company), are intended solely for discussion
purposes and are not intended as, and do not constitute, an offer to sell or a solicitation of an offer to buy any security, and should not
be relied upon by you in evaluating the merits of investing in any securities. These materials are not intended for distribution to, or use
by, any person or entity in any jurisdiction or country where such distribution or use is contrary to local law or regulation. This
information is confidential and should not be distributed, in whole or in part, beyond the recipient and its advisors.

The Company believes the information contained in this document to be reliable but makes no warranty or representation, whether
express or implied, and assumes no legal liability for the accuracy, completeness or usefulness of any information disclosed. Any
estimates, investment strategies, and views expressed in this document are based upon current market conditions and/or data and
information provided by unaffiliated third parties and is subject to change without notice.

This document may contain forward-looking information and forward-looking statements within the meaning of applicable Canadian
securities legislation. Forward-looking information includes, but is not limited to, statements about strategic plans, including the
Company's ability to implement its business development strategy. Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic
and competitive uncertainties and contingencies. Forward-looking statements involve known and unknown risks, uncertainties and other
factors that may cause actual financial results, performance or achievements to be materially different from the estimated future results,
performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not
guarantees of future performance. All forward-looking information contained herein are given as of the date hereof and are based upon
the opinions and estimates of management and information available to management as at the date hereof. Except as required by law,
the Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information,
events or otherwise. Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains
information obtained by the Company from third parties, including but not limited to market data. The Company believes such
information to be accurate but has not independently verified such information. To the extent such information was obtained from third
party sources, there is a risk that the assumptions made and conclusions drawn by the Company based on such representations are not
accurate.

2
CANNABIS REGULATION IN CANADA

Court mandated Section 56 Exemptions to the Controlled Drugs And Substances Act
1999 2001 Right to possess marijuana for medical purposes

Marihuana Medical Access Regulations (MMAR)


Access to dried marijuana for medical purposes
& 2001 2013
Patients can produce their own, designate someone to produce for them, or
patients can purchase directly from Health Canada supply (1 producer)

Marihuana For Medical Purposes Regulations (MMPR)


2014 2016 Created commercial industry responsible for production and distribution
Licensed Producers (LPs) supply medical cannabis by direct mail

Access to Cannabis For Medical Purposes Regulations (ACMPR)


2016 Present LPs by mail, home cultivation, and designated production all permitted
Patients can use, possess, and alter different forms of cannabis (e.g. oils)

We will legalize, regulate, and restrict access to marijuana Justin Trudeau


Coming Soon Liberal government election platform and re-confirmed in throne speech
(TBD) Majority government to recommend legislation by the Spring of 2017

Liberal Party of Canada. Conservative Party of Canada.

3
COMPANY OVERVIEW
Cronos is a geographically diversified and vertically integrated cannabis company with one of the largest and most
scalable operating platforms in the global medical cannabis industry.

The newly implemented management teams mandate is to capture market share in the emerging cannabis industry by
expanding its existing production platform, developing its brands and exportable intellectual property, and pursuing
incremental distribution channels.

Two Geographically Diversified Management Team with Proven Minority Investments Provide
Canadian Licensed Producers Transaction Capabilities Significant Optionality

100% OWNED LICENSED ASSETS RECENT TRANSACTIONS1 EQUITY ACCOUNTED INVESTMENTS

1. See appendix E for more detail.

4
MANAGEMENT TEAM

Michael Gorenstein President, CEO & Chairman


M&A and capital markets expertise
Former Partner at Alphabet Ventures LLC
Former Corporate Attorney at Sullivan & Cromwell
J.D. from University of Pennsylvania Law School

David Hsu Chief Operating Officer


Significant consulting and private equity experience
Financial and operational restructuring expertise
Bachelor of Science in Business Management from Babson College
Lean Six Sigma Black Belt

William Hilson Chief Financial Officer


Regional CFO for two listed multinational pharmaceutical companies
Experience in M&A and licensing deals in pharmaceutical sector
Graduated from University of Toronto, Western and holds a CPA designation
Masters of Science degree in Clinical Biochemistry and Honours Bachelor of Genetics

Eric Klein Marketing and Communications


CPG brand management, marketing, and distribution expertise
Senior Brand Manager at PepsiCo
Prior experience with Kraft/Mondelez, Chobani and Sara Lee
MBA from University of Chicago Booth School of Business

5
THE PEACE NATURALS PROJECT

OVERVIEW
Cronos Group acquired 100% of The Peace Naturals Project (PNP) in
September 2016
PNP has to date registered 3,400 patients and is licensed to sell 2,500
kg of medical cannabis per year
PNP is situated on over 90 acres of land with three production
buildings
Largest site of any LP in Ontario
~4,200 kg of capacity within existing infrastructure
Three production buildings with 40,000+ sq. ft.
Over 100 unique genetics in seed bank

CURRENT INFRASTRUCTURE
Over 40,000 sq. ft. of established operating space
Building 1 8,720 sq. ft. original licensed production space
Building 2 & 3 30,000 sq. ft. of total production space
Additional 80+ acres of flat land, appropriately zoned for development

Situated on over 90 acres of land

6
IN THE ZONE PRODUCE

OVERVIEW
In The Zone is a licensed producer based in Okanagan Valley, BC
Currently licensed to sell 100 kg per annum
Situated on 31 acres of agricultural land zoned appropriately for
cannabis production
Current pilot facility of approximately 2,000 sq. ft.
Premium genetics sourced from Whistler Medical Marijuana
Company (WMMC)
On-site artesian well providing free source of water for cannabis
production (200+ gallon per minute capacity) Recently acquired incremental 17 acres

RECENT INITIATIVES
Completed multiple harvests in newly renovated facility
Completed Health Canada sales license inspection
Purchased adjacent 17 acre property to merge with existing 14 acres
Ongoing engineering and design work for onsite expansion facility
Entered industry first strategic joint venture with Canadian First
Nations, Indigenous Roots
Newly renovated facility

7
INDIGENOUS ROOTS

On December 6, 2016, Cronos announced an industry first strategic joint venture with Canadian First Nations, and the
formation of a new company and brand, Indigenous Roots
The joint venture provides Cronos with access to non-dilutive growth capital, significant economic exposure to a new
consumer demographic, and provides opportunities for incremental domestic and international expansion opportunities on
First Nation reserves

50% JOINT VENTURE PARTNER 50% JOINT VENTURE PARTNER

INDIGENOUS ROOTS

Newly formed entity will commit to First Nations Finance Company


remaining First Nations
owned/operated
JV Partnership will seek to source and
license additional facilities on First
Cronos will provide the land, license, IP, Nations reserves Phil Fontaine will lead the joint venture
and engineering expertise
Foundation for a national platform FNFC will construct and finance the
Cronos will also provide ongoing through which cannabis medication operation of the flagship Indigenous
training for the First Nations staff in a can be provided to millions of Roots facility and future operations
Health Canada compliant environment underserved patients living both on
and off reserves Initial facility will be located on Cronos
Cronos will share in the operating wholly owned subsidiary property, In
profits on a 50/50 basis, and as a 50/50 The Zone Produce, in British Columbia
equity partner

8
PEDANIOS

On December 28, 2016, Cronos announced an exclusive North American


supply agreement with Pedanios GmbH (Pedanios) for distribution of
medical cannabis into the EU and Switzerland.
This agreement supplements a prior co-branded supply agreement
between the Companies that was entered into in October 2016 under
Germanys former more restrictive medical cannabis regulations.
On January 19, 2017, the Germain parliament voted unanimously to
legalize medical marijuana in Germany, to drastically simplify the
prescription process, increase the number of eligible conditions for
cannabis medication, and have implemented policy that will provide
health insurance coverage for patients
Pedanios is one of very few that currently distributes Germanys
medical cannabis supply to a network of over 200 pharmacies and
holds one of a limited number of medical cannabis business licenses in
Germany
Cronos has granted Pedanios an exclusive license to market, sell,
commercialize, and distribute Company products into selected and
appropriately regulated European jurisdictions for an initial term of 3 years

Pedanios-branded flower products

9
NEAR-TERM MILESTONES AND CATALYSTS

Cronos Group is focused on executing its rebranding and global commercialization strategy

Goal 1: Optimization of Domestic Operations, Expansion Initiatives, and Brand Development

Goal 2: Non-Capital Intensive Global Expansion and Joint Venture Initiatives

PHASE 1 ONGOING OR COMPLETE PHASE 2 MEDIUM TERM

Obtain sales license at In The Zone (Complete) Leverage expansion optionality at Peace
Naturals and In The Zone
Optimize Peace Naturals production facilities
Review and evaluate minority investments
Develop exportable intellectual property,
expertise, and know-how
Establish domestic and international distribution
relationships and strategic joint ventures
Explore opportunities to monetize non-core
assets
Develop additional brands to pre-position for the
potential recreational market
Pursue additional international partnership,
export relationships, and joint venture
opportunities
Re-branding of and launch of In The Zone sales
platform

10
APPENDIX
APPENDIX A

Michael Gorenstein President, CEO & Chairman


Mr. Gorenstein is a partner at Alphabet Ventures LLC, a multi-strategy investment management firm located in New York City. Prior to
Alphabet Management, Mr. Gorenstein was the VP and General Counsel of Saiers Capital LLC and a corporate attorney at Sullivan & Cromwell
where he focused on Mergers and Acquisitions and Capital Market transactions. Mr. Gorenstein graduated from the University of
Pennsylvania Law School with a JD, the Wharton School at University of Pennsylvania with a certificate in BEPP and the Kelley School of
Business at Indiana University with a BSB in Finance.

David Hsu Chief Operating Officer


Prior to joining Cronos, Mr. Hsu spent over 10 years with Deloitte/CRG Partners, a premier turnaround consulting firm where he operated and
managed distressed companies with revenues in excess of $500M. Prior to Deloitte/CRG, Mr. Hsu worked as a financial analyst for the
nations fifth largest mass transit system, where he assisted in the allocation and management of a $1.2 billion operating budget and selected
capital projects. Mr. Hsu is also a member of the Turnaround Management Association, the Association for Operations Management, and is a
Certified Insolvency and Restructuring Advisor (CIRA). His expertise includes financial and operational restructuring, growth creation, and lean
manufacturing. Mr. Hsu graduated from Babson College with a Bachelor of Science in Business Management and is a certified Lean Six Sigma
Black Belt.

William Hilson Chief Financial Officer


Mr. Hilson is a Certified Public Accountant (CPA) and has spent over 15 years as regional CFO for two publicly listed multinational
pharmaceutical companies Merck KGaA and Serono S.A. His expertise includes financial operations, strategy, performance management,
sales & marketing, clinical trial management, international tax, debt & equity financing; including a NASDAQ initial public offering. Prior to
joining Cronos Group, Mr. Hilson was also involved in a number of mergers & acquisitions and licensing deals in the pharmaceutical sector.
Mr. Hilson graduated from the University of Toronto and The University of Western Ontario where he earned a Master of Science degree in
Clinical Biochemistry and an Honours Bachelor of Genetics. Mr. Hilson also holds an Audit Committee Board Member designation from The
Directors College, McMaster University.

12
APPENDIX B

Jason Adler Director


Mr. Adler is the CEO and Managing Member of Alphabet Ventures, LLC, a captive investment vehicle operating in a wide range of domains
including growth equity, established companies with growth perspective, and creative debt vehicles. Prior to Alphabet Ventures Mr. Adler was
the co-founder and CEO of Alphabet Management, LLC, a New York based volatility fund, that focused on identifying mispriced assets across
various industries, asset classes and geographies. Mr. Adler also founded Geronimo, LLC, an AMEX member broker dealer that made markets
in equity options and began his career as a market maker at G&D Trading, an AMEX member market maker. He received his B.A. from the
University of Rhode Island.

Michael Krestell Director


Mr. Krestell has been the President of M Partners Inc. since 2013 and prior thereto he was the firms Managing Director of Equity Research.
Mr. Krestell received a Starmine award by being the number 4 ranked stock picker in Canada in 2009. He received an MBA with distinction
from the Schulich School of Business and is a CFA Charterholder.

Alan Friedman Director


Mr. Friedman is an attorney and has played an integral role in the establishment, acquisitions, financings and go-public transactions for many
Canadian companies. He is co-founder and Director of TSX-V listed companies, Adira Energy Ltd. and Eco (Atlantic) Oil and Gas Ltd. Mr.
Friedman was also co-founder of Auryx Gold Corp. a TSX listed gold company sold to B2 Gold Corp for $150mm in 2012. He is also CEO of
Rivonia Capital, a Canadian boutique finance and facilitation company specializing in public market transactions.

Michael Gorenstein President, CEO & Chairman

13
APPENDIX C

PRODUCER LICENSE OWNERSHIP HIGHLIGHTS

Licensed for sale up to 100 kg (per year)


Situated on 31 acres of land
Licensed 100.0%
Current ~2,000 sq. ft. pilot facility
Located in the Okanagan Valley, B.C.

Licensed for sale of up to 2,500 kg (per year)


90.5 acres of land
Licensed 100.0%
Current facilities total ~40,000 sq. ft.
Located near Toronto, ON

Licensed for sale of up to 600 kg (per year)


Current facilities total ~12,000 sq. ft.
Licensed 21.4%
Expansion opportunity of over 120,000 sq. ft.
Located in Whistler, B.C.

14
APPENDIX D

PRODUCER LICENSE OWNERSHIP HIGHLIGHTS

Licensed to produce up to 625 kg (per year)


Licensed 6.0% Over 1 acre of land, located near Napanee, ON
Current facilities total ~14,500 sq. ft.

Licensed to produce up to 350 kg (per year)


Licensed 1.9% 80 acres of land, located near Gatineau, QC
Current facilities total ~42,000 sq. ft.

Built out facilities awaiting pre-license inspection


Pre-License Up to 30.0% 2.5 acres of land, located near Victoria, B.C.
Current facilities total ~5,500 sq. ft.

Built out facilities awaiting pre-license inspection


Pre-License Up to 8.5% Located near Toronto, ON
Current facilities total ~4,000 sq. ft.

15
APPENDIX E

Since beginning the implementation of the new executive team in May of 2016, Cronos has streamlined the portfolio and
negotiated/executed multiple value creating transactions

TRANSACTIONS

May 16, 2016 Raised $6m via non-brokered private placement

Consolidated Peace Naturals Project; acquired remaining 74% for $9.5m funded
September 6, 2016
with $15m concurrent non-brokered private placement (at a premium to market)

September 29, 2016 Expanded land ownership package at ITZ to 31 acres

October 6, 2016 PharmaCan Capital officially rebranded as Cronos Group

Exported first shipment of medical cannabis co-branded with Pedanios GmbH for
October 11, 2016
distribution to medical patients in Germany

Divested minority stake in Vert Medical. $422,933 of debt repaid and 7,334 shares
November 1, 2016
of CGC with up to 29,498 CGC shares payable under certain circumstances

16